Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome

Abstract EN

The etiology of nephrotic syndrome is complex and ranges from primary glomerulonephritis to secondary forms.

Patients with nephrotic syndrome often need immunosuppressive treatment with its side effects and may progress to end stage renal disease.

This review focuses on recent advances in the treatment of primary causes of nephrotic syndrome (idiopathic membranous nephropathy (iMN), minimal change disease (MCD), and focal segmental glomerulosclerosis (FSGS)) since the publication of the KDIGO guidelines in 2012.

Current treatment recommendations are mostly based on randomized controlled trials (RCTs) in children, small RCTs, or case series in adults.

Recently, only a few new RCTs have been published, such as the Gemritux trial evaluating rituximab treatment versus supportive antiproteinuric and antihypertensive therapy in iMN.

Many RCTs are ongoing for iMN, MCD, and FSGS that will provide further information on the effectiveness of different treatment options for the causative disease.

In addition to reviewing recent clinical studies, we provide insight into potential new targets for the treatment of nephrotic syndrome from recent basic science publications.